肥胖症及其相关并发症的临床研究以及肥胖症患者不同糖代谢状态下血清相关因子变化的研究
|
摘要
目的：
肥胖症已经成为危害人类健康的重要疾病,全球患病率显著升高,特别是在中国等发展中国家。肥胖症与心脑血管疾病、高血压、2型糖尿病、血脂紊乱、睡眠呼吸暂停综合征等疾病的发生有密切的关系。本研究拟探讨单纯性肥胖症患者相关并发症的患病情况。
方法：
对北京协和医院内分泌科2000～2013年就诊的552例单纯性肥胖症患者的临床资料进行回顾性分析,建立Access数据库,并对数据库资料进行统计分析,对肥胖症患者合并高血压、血脂紊乱、糖代谢异常、胰岛素抵抗、脂肪肝、睡眠呼吸暂停综合征、女性月经紊乱等肥胖常见合并症的患病情况及其与体重指数(BMI)的关系进行分析。
结果：
1、552名肥胖症患者平均年龄为26.3±13.0岁,平均BMI为35.57±6.87kg/m2;其中男性200人,女性352人。
2、552名肥胖症患者中,儿童青少年患者155人,平均年龄14.1±2.4岁,男生76人,女生79人。纳入统计分析的青少年肥胖症患者110人,其中男性45人,女性65人。男性患者高血压患病率为44.2%,高血压患病率与BMI无显著相关性(P=0.50)；女性患者高血压患病率为58.3%,高血压患病率与BMI正相关。严重肥胖组(BMI≥35.0kg/m2)高血压患病率显著高于一般肥胖组(P=0.008,OR值=4.620,95%CI为[1.349～17.921])。青少年女性肌酐(Cr)、超敏C反应蛋白(hsCRP)、稳态模型胰岛素抵抗指数(HOMA-IR)与BMI呈显著正相关(P值分别为0.04,0.003和0.04),游离甲状腺素(FT4)与BMI呈显著负相关(P=0.03)。
3、552名肥胖症患者中,成年患者397人,平均年龄31.1±12.4岁；其中男性124人,女性273人。对这组人群临床资料的统计分析表明：①成年男性高血压患病率为50.4%,高血压患病率与BMI呈显著正相关(P<0.001)；低高密度脂蛋白胆固醇(HDL-C)血症患病率为52.7%,与BMI呈显著正相关(P=0.02)；代谢综合征(MS)患病率60.3%,与BMI呈显著正相关(P<0.001)；而高脂血症、2型糖尿病、脂肪肝和OSAS的患病率均与BMI无统计学相关性,P值分别为0.62、0.21、0.66和0.13。②成年女性：高血压患病率为31.2%,与BMI呈显著正相关,P值=0.002；低HDL-C血症患病率为23.2%,与BMI呈显著正相关,P值=0.005：2型糖尿病患病率为14.3%,与BMI呈显著正相关,P值=0.03;脂肪肝与BMI呈显著正相关,P值=0.004；代谢综合征患病率为69.9%,与BMI呈显著正相关,P值=0.04;OSAS患病率为94.8%,患OSAS组的平均BMI显著高于无OSAS组,P值=0.007。③对于18-45岁育龄期妇女,BMI与月经紊乱呈正相关,P值=0.02。④在血清学生化指标与BMI关系的统计中,在男性和女性肥胖症患者中,直接胆红素(DBil)、尿酸(UA)、hsCRP、空腹血糖(FBG)、空腹胰岛素(FINS)、HOMA-IR与BMI呈正相关,白蛋白(Alb)、Cr、HDL-C、载脂蛋白B(ApoB)、睾酮(T)与BMI呈负相关；而在女性肥胖症患者中,谷氨酸氨基转移酶(ALT)、γ-谷氨酰转移酶(GGT)、总胆红素(TBil)、游离脂肪酸(FFA)、三碘甲状腺原氨酸(T3)与BMI呈正相关。
结论：
本研究发现在单纯性肥胖症的青少年患者中高血压的发生率较高,而且高血压的发生与BMI呈显著正相关；在单纯性肥胖症男性成年患者中,高血压、低HDL-C血症、代谢综合征等并发症的发生率较高,并与BMI正相关；而在单纯性肥胖症女性成年患者中,除了高血压、低HDL-C血症、代谢综合征等并发症的发生率较高外,2型糖尿病、脂肪肝的发生率也较高,并均与BMI呈显著正相关。
目的：
在肥胖症患者中,2型糖尿病、糖耐量受损或胰岛素抵抗的发生率与体重正常者相比是显著增加的,血清脂肪细胞因子和肌肉细胞因子可能在其中发挥了重要作用。本研究旨在探讨肥胖症患者不同糖代谢状态下,血清脂肪细胞因子包括肿瘤坏死因子-α (TNF-α)、Glypican-4(GPC-4)及高分子量脂联素(HMW-APN)和肌肉细胞因子Irisin水平的变化及其与肥胖相关糖脂代谢生化指标的相关性。
方法：
收集1146名2003～2013年就诊于北京协和医院内分泌科以及参与全国流行病学调查的患者信息,分析其糖代谢状态与肥胖相关因素之间的关系。这些患者均为成年人,收集的临床资料包括身高,体重、BMI、空腹胰岛素、血糖血脂等生化指标,并经3小时口服葡萄糖耐量试验(OGTT),准确判断其糖代谢状况,其中男性431人,女性715人。根据肥胖症患者的糖代谢状况,将部分病人分为以下几组：OB1组(40人)：糖耐量、胰岛素水平均正常的肥胖症患者：OB2组(39人)：糖耐量正常、高胰岛素水平的肥胖症患者；OB3组(50人)：糖耐量受损(IGT)的肥胖症患者；OB4组(41人)：患2型糖尿病(DM)的肥胖症患者。然后从本课题组已经收集的正常人数据库中选取健康正常对照者38人(糖耐量、胰岛素水平均正常且体重正常)。采用用酶联免疫吸附方法(ELISA)测定上述5组人群中,血清HMW-APN、GPC-4、TNF-α及Irisin的水平。
结果：
1、临床血清学生化指标的分析表明：①与糖代谢正常的人群相比,IGT和DM组的病人更易合并高血压；而IGT、DM及IFG(空腹血糖受损)+IGT组的病人更易合并高脂血症；糖代谢状态与低HDL-C血症患病情况无明显相关性。②糖代谢状态与血清学生化指标的关系：IGT和DM组与糖代谢正常组相比,ALT和AST水平显著性升高(ALT分别升高51.1%和38.5%,AST分别升高29.1%和23.0%);DM组与糖代谢正常组及IFG组相比,Cr水平显著性下降(分别下降了11.0%和13.0%); IGT、IFG+IGT和DM组与糖代谢正常组相比TG水平显著性升高(分别升高了25.7%、29.9%和73.6%),DM组与IGT组相比TG水平显著性升高(升高了38.1%); IGT、IFG+IGT和DM组与糖代谢正常组相比,TC水平显著升高(分别升高了9.5%、8.0%和14.3%)；IGT和DM组与糖代谢正常组相比,LDL-C的水平显著升高(分别升高了14.1%和14.4%)：IFG+IGT组与IGT组相比,HDL-C的水平显著性升高(升高了12.7%)；DM组与糖代谢正常组相比,UA水平显著升高(升高了9.1%)；IGT和DM组与糖代谢正常组相比,HOMA-IR水平显著升高(分别升高了32.6%和71.0%)。
2、血清脂肪细胞因子和肌肉细胞因子的测定结果表明：①HMW-APN浓度在从正常对照组到OB4组是呈逐渐下降趋势的,OB4组浓度是正常对照组的60.2%,差异具有显著性,说明随着糖代谢状况的恶化,保护性脂肪细胞因子HMW-APN的水平逐渐降低。女性的HMW-APN浓度在各组中都是明显高于男性的；在男性和女性中,HDL-C与HMW-APN浓度呈正相关,体脂、BMI、ALT、FINS、LDL-C和HOMA-IR与HMW-APN浓度呈负相关；在女性中还有AST、TG和TC与HMW-APN浓度呈负相关。②GPC-4的浓度从正常对照组到OB4组呈升高趋势,OB4组浓度是正常对照组的1.36倍；且在男性和女性中浓度不一,除了在OB1组男性GPC-4浓度略低于女性外(无显著性差异),各组均是男性GPC-4水平高于女性；在男性和女性中,BMI、ALT、AST、FINS和HOMA-IR与GPC-4浓度呈正相关；在男性中还有体脂、TC和LDL-C与GPC-4浓度呈正相关,年龄和HDL-C与GPC-4浓度呈负相关；③TNF-α在各组之间浓度无显著性差异,在男性和女性中,BMI、FINS和HOMA-IR与TNF-α浓度呈正相关,HDL-C与TNF-α浓度呈负相关；在女性中还有年龄与TNF-α浓度呈显著正相关。④Irisin在OB3和OB4组浓度高于其它组,且在男性中与年龄呈负相关(均以P<0.05为有统计学差异)。
结论：
与糖代谢正常的人群相比,糖耐量受损患者更易合并高血压和高脂血症。随着糖代谢状况的恶化,血清保护性脂肪细胞因子HMW-APN的浓度逐渐降低；而炎性因子TNF-α的水平没有显著改变；新型脂肪细胞因子GPC-4和新型肌肉细胞因子Irisin的浓度均出现逐渐升高的趋势；提示这些新型的细胞因子通过增加自身的水平抑制TNF-α等炎性因子的分泌,试图延缓糖代谢状况恶化的进程。
Object:
Now obesity is an important disease that threats public health, sharp increases in the prevalence of obesity have occurred worldwide, especially in China. Obese patients are at risk for developing coronary heart disease, hypertension, type2diabetes, dyslipidemia, sleep apnea et al. The aim of this study is to investigate the morbidity and the condition of complications of obesity.
Method:
We retrospectively analyze the clinical data of552patients who have been diagnosed simple obesity from2000to2013in the endocrinology department of Peking Union Medical Colledge Hospital. We design an access database, and then we analyze the association between the prevalence of hypertension, hyperlipidemia, impaired glucose tolerance, irregular menses et al with body mass index (BMI) of the obese patients using statistical methods.
Results:
1. The mean age of the552obese patients is26.3±13.0years of age, and the mean BMI is35.57±6.87kg/m2. Totally there are200male patients and352female patients.
2. There are155minors among the552patients, with a mean age of14.1±2.4,76of which are male and79are female. One hundred and ten minors are brought into statistical analysis,45of which are male and65are female. The results of the statistical analysis are:In minor male, the prevalence of hypertension is44.2%, and is not correlated with BMI, with the P value=0.50. In minor female, the prevalence of hypertension is58.3%, and is positively correlated with body mass index (BMI), with the P value=0.008, OR=4.62and95%confidence interval [1.35-17.92]. Creatinine (Cr), hypersensitive C reactive protein (hsCRP) and homeostasis model assessment of insulin resistance index (HOMA-IR) are positively correlated with BMI, and free thyroxine (FT4) is negatively correlated with BMI.
3. In all397adults are brought into statistical analysis, in which there are124male and273female. The results of the statistical analysis are:①In male adults, the incidence of hypertension is50.4%, and is correlated with BMI, with the P values<0.001. The prevalence of low HDL-C is52.7%, and is correlated with BMI, with the P value=0.02. And the prevalence of metabolic syndrome is60.3%, and is correlated with BMI, with the P value<0.001. However the incidence of hyperlipidemia, T2DM, fatty liver and OSAS are not correlated with BMI, with the P value=0.62,0.21,0.66and0.13, respectively.②In female adults, the incidence of hypertension is31.2%, and is correlated with BMI, with the P values=0.002. However the prevalence of low high density lipoprotein cholesterol (HDL-C) is23.2%, and is correlated with BMI, with the P value=0.005. The incidence of type2diabetes mellitus (T2DM) is14.3%, and is correlated with BMI, with the P value=0.03. And the incidence of fatty liver is correlated with BMI, with the P value=0.004. The prevalence of metabolic syndrome is69.9%, and is correlated with BMI, with the P value=0.04. The prevalence of obstructive sleep apnea syndrome (OSAS) is94.8%, and the BMI of the sick group of OSAS is markedly higher than normal group, with the P value=0.007.③For women between18and45years of reproductive age, BMI is positively correlated with irregular menses, with the P value=0.02.④In male and female adults, direct bilirubin (DBil), uric acid (UA), hsCRP, fasting blood glucose (FBG), fasting insulin (FINS) and HOMA-IR are positively correlated with BMI, and albumin (Alb), Cr, HDL-C, apolipoproteinB (ApoB) and testosterone (T) are negatively correlated with BMI. While in female adults, alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), total bilirubin (TBil), free fatty acid (FFA) and triiodothyronine (T3) are positively correlated with BMI.
Conclusion:
To sum up, we find that in simple obese minors, the prevalence of hypertension is higher and is positively correlated with BMI. In simple obese male adults, hypertension, low HDL-C and metabolic syndrome are positively correlated with BMI. And despite hypertension, low HDL-C and metabolic syndrome, type2diabetes mellitus, fatty liver are also positively correlated with BMI in simple obese female adults.
Object:
In obese patients, the prevalence of type2diabetes mellitus, impaired glucose tolerance and insulin resistance is sharp increased compared with normal weight people. The serum levels of certain adipokines and muscle factors may play an important role in it. Our study tries to investigate the relationship between changes of serum adipokines and muscle factor levels and obesity-related metabolic factors. The adipokines in our study include high-molecular-weight adiponectin, glypican-4, tumor necrosis factor-a and the muscle factor refers to irisin.
Method:
We select1146clinical cases from endocrinology department of Peking Union Medical College Hospital and do the statistical analysis. We analyze the relationship between the glucose metabolism status and several serum factors. All patients being analyzed are adults and have3hour oral glucose tolerance test (OGTT) results. All patients have exact diagnosis of their glucose metabolism status.413men and715women are included. Then we select208testees and divide them into5groups:normal control group (patients with normal glucose tolerance, normal insulin level and normal weight), OBI group (obese patients with normal glucose tolerance and normal insulin level), OB2group (obese patients with normal glucose tolerance but high insulin level), OB3group (obese patients with impaired glucose tolerance [IGT]) and OB4group (obese patients with type2diabetes mellitus [DM]). There are totally38patients in normal control group,40in OBI group,39in OB2group,50in OB4group and41in OB4group. Each one of the five groups has no statistical difference of age and sex composition with every other group. We use their fasting serum sample in the test. Since there are three reagent kits in total, for quality control's sake, we select one37-years-old male control and add his serum sample on all three kits (once for each kit). So there are210samples in total and300μl for each. Then we use enzyme-linked immunosorbent assay (ELISA) to test the level of irisin, TNF-a, glypican-4and HMW-APN of the serum sample.
Results:
1. The results of the cases analysis:①Compared with normal glucose metabolism (NGM) people, patients in the impaired glucose tolerance (IGT) group and type2diabetes mellitus (DM) group are more likely to combine hypertension. Patients in the IGT, DM, and impaired fasting glucose (IFG)+IGT group are more likely to combine hyperlipidemia as compared with NGM people. Meanwhile the incidence of low HDL-C is not correlated with glucose metabolism status.②For the serum factors, the level of ALT and AST are markedly higher in IGT and DM patients compared with NGM people (elevated51.1%and38.5%for AST, and29.1%and23.0%for AST). Compared with NGM people and IFG patients, patients in DM group have markedly lower Cr level (decreased11.0%and13.0%, separately). Patients in IGT, DM, and IFG+IGT group have markedly higher TG level compared with NGM people(elevated25.7%,29.9%and73.6%, separately), and patients in DM group have markedly higher TG level compared with the patients in IGT group (elevated38.1%). At the same time, patients in IGT, DM, and IFG+IGT group have markedly higher TC serum level compared with NGM people (elevated9.5%,8.0%and14.3%, separately). Compared with NGM people, patients in IGT and DM group have markedly higher LDL-C level (elevated14.1%and14.4%, separately). Patients in IFG+IGT group have markedly higher HDL-C level compared with IGT group (elevated12.7%). Compared with NGM people, patients in DM group have markedly higher UA level (elevated9.1%). Meanwhile patients in IGT and DM group have markedly higher HOMA-IR level compared with NGM people (elevated32.6%and71.0%, separately).
2. The results of the four serum factors:①The levels of HMW-APN trend down from normal control group (NOR) to OB4group, the level of HMW-APN in OB4group is only60.2%of that of NOR, and the level of HMW-APN is clearly higher in female than in male. In male and female, HDL-C is positively correlated with the level of HMW-APN, while body fat, BMI, ALT, FINS, LDL-C and HOMA-IR are negatively correlated with the level of HMW-APN. While in female, AST, TG and TC are negatively correlated with the level of HMW-APN.②From NOR to OB4group, the levels of GPC-4trend up. The level of GPC-4in OB4group is1.36fold larger than that of NOR. The levels of GPC-4are different in male and female; whereas it is a little bit lower in male than in female in group1(there is no statistical significance), the levels of GPC-4in male are higher than that in female in all the other groups. In male and female, BMI, ALT, AST, FINS and HOMA-IR are positively correlated with the level of GPC-4, while in male, body fat, TC and LDL-C are positively correlated with the level of GPC-4, and age is negatively correlated with the level of GPC-4.③There are no statistical differences between the levels of TNF-a in different groups. In male and female, BMI, FINS and HOMA-IR are positively correlated with the level of TNF-α, and the level of HDL-C is negatively correlated with the level of TNF-a. While in female, age is markedly positively correlated with the level of TNF-a.④The level of irisin is higher in patients of OB3and OB4groups than other groups, and in male age is markedly negatively correlated with the level of irisin (P<0.05).
Conclusion:
Compared with normal glucose metabolism people, patients with impaired glucose tolerance are more likely to combine hypertension and hyperlipidemia. As the glucose metabolism status goes worse, the level of the protective adipokine HMW-APN trends down, meanwhile there are no statistical significances between the levels of the inflammatory factor TNF-a. However the levels of the new adipokine GPC-4and the new muscle factor Irisin trends up, indicating that these new cytokines depress the secretion of inflammatory factors like TNF-a and try to delay the exacerbation process of glucose metabolism status.
肥胖症已经成为危害人类健康的重要疾病,全球患病率显著升高,特别是在中国等发展中国家。肥胖症与心脑血管疾病、高血压、2型糖尿病、血脂紊乱、睡眠呼吸暂停综合征等疾病的发生有密切的关系。本研究拟探讨单纯性肥胖症患者相关并发症的患病情况。
方法：
对北京协和医院内分泌科2000～2013年就诊的552例单纯性肥胖症患者的临床资料进行回顾性分析,建立Access数据库,并对数据库资料进行统计分析,对肥胖症患者合并高血压、血脂紊乱、糖代谢异常、胰岛素抵抗、脂肪肝、睡眠呼吸暂停综合征、女性月经紊乱等肥胖常见合并症的患病情况及其与体重指数(BMI)的关系进行分析。
结果：
1、552名肥胖症患者平均年龄为26.3±13.0岁,平均BMI为35.57±6.87kg/m2;其中男性200人,女性352人。
2、552名肥胖症患者中,儿童青少年患者155人,平均年龄14.1±2.4岁,男生76人,女生79人。纳入统计分析的青少年肥胖症患者110人,其中男性45人,女性65人。男性患者高血压患病率为44.2%,高血压患病率与BMI无显著相关性(P=0.50)；女性患者高血压患病率为58.3%,高血压患病率与BMI正相关。严重肥胖组(BMI≥35.0kg/m2)高血压患病率显著高于一般肥胖组(P=0.008,OR值=4.620,95%CI为[1.349～17.921])。青少年女性肌酐(Cr)、超敏C反应蛋白(hsCRP)、稳态模型胰岛素抵抗指数(HOMA-IR)与BMI呈显著正相关(P值分别为0.04,0.003和0.04),游离甲状腺素(FT4)与BMI呈显著负相关(P=0.03)。
3、552名肥胖症患者中,成年患者397人,平均年龄31.1±12.4岁；其中男性124人,女性273人。对这组人群临床资料的统计分析表明：①成年男性高血压患病率为50.4%,高血压患病率与BMI呈显著正相关(P<0.001)；低高密度脂蛋白胆固醇(HDL-C)血症患病率为52.7%,与BMI呈显著正相关(P=0.02)；代谢综合征(MS)患病率60.3%,与BMI呈显著正相关(P<0.001)；而高脂血症、2型糖尿病、脂肪肝和OSAS的患病率均与BMI无统计学相关性,P值分别为0.62、0.21、0.66和0.13。②成年女性：高血压患病率为31.2%,与BMI呈显著正相关,P值=0.002；低HDL-C血症患病率为23.2%,与BMI呈显著正相关,P值=0.005：2型糖尿病患病率为14.3%,与BMI呈显著正相关,P值=0.03;脂肪肝与BMI呈显著正相关,P值=0.004；代谢综合征患病率为69.9%,与BMI呈显著正相关,P值=0.04;OSAS患病率为94.8%,患OSAS组的平均BMI显著高于无OSAS组,P值=0.007。③对于18-45岁育龄期妇女,BMI与月经紊乱呈正相关,P值=0.02。④在血清学生化指标与BMI关系的统计中,在男性和女性肥胖症患者中,直接胆红素(DBil)、尿酸(UA)、hsCRP、空腹血糖(FBG)、空腹胰岛素(FINS)、HOMA-IR与BMI呈正相关,白蛋白(Alb)、Cr、HDL-C、载脂蛋白B(ApoB)、睾酮(T)与BMI呈负相关；而在女性肥胖症患者中,谷氨酸氨基转移酶(ALT)、γ-谷氨酰转移酶(GGT)、总胆红素(TBil)、游离脂肪酸(FFA)、三碘甲状腺原氨酸(T3)与BMI呈正相关。
结论：
本研究发现在单纯性肥胖症的青少年患者中高血压的发生率较高,而且高血压的发生与BMI呈显著正相关；在单纯性肥胖症男性成年患者中,高血压、低HDL-C血症、代谢综合征等并发症的发生率较高,并与BMI正相关；而在单纯性肥胖症女性成年患者中,除了高血压、低HDL-C血症、代谢综合征等并发症的发生率较高外,2型糖尿病、脂肪肝的发生率也较高,并均与BMI呈显著正相关。
目的：
在肥胖症患者中,2型糖尿病、糖耐量受损或胰岛素抵抗的发生率与体重正常者相比是显著增加的,血清脂肪细胞因子和肌肉细胞因子可能在其中发挥了重要作用。本研究旨在探讨肥胖症患者不同糖代谢状态下,血清脂肪细胞因子包括肿瘤坏死因子-α (TNF-α)、Glypican-4(GPC-4)及高分子量脂联素(HMW-APN)和肌肉细胞因子Irisin水平的变化及其与肥胖相关糖脂代谢生化指标的相关性。
方法：
收集1146名2003～2013年就诊于北京协和医院内分泌科以及参与全国流行病学调查的患者信息,分析其糖代谢状态与肥胖相关因素之间的关系。这些患者均为成年人,收集的临床资料包括身高,体重、BMI、空腹胰岛素、血糖血脂等生化指标,并经3小时口服葡萄糖耐量试验(OGTT),准确判断其糖代谢状况,其中男性431人,女性715人。根据肥胖症患者的糖代谢状况,将部分病人分为以下几组：OB1组(40人)：糖耐量、胰岛素水平均正常的肥胖症患者：OB2组(39人)：糖耐量正常、高胰岛素水平的肥胖症患者；OB3组(50人)：糖耐量受损(IGT)的肥胖症患者；OB4组(41人)：患2型糖尿病(DM)的肥胖症患者。然后从本课题组已经收集的正常人数据库中选取健康正常对照者38人(糖耐量、胰岛素水平均正常且体重正常)。采用用酶联免疫吸附方法(ELISA)测定上述5组人群中,血清HMW-APN、GPC-4、TNF-α及Irisin的水平。
结果：
1、临床血清学生化指标的分析表明：①与糖代谢正常的人群相比,IGT和DM组的病人更易合并高血压；而IGT、DM及IFG(空腹血糖受损)+IGT组的病人更易合并高脂血症；糖代谢状态与低HDL-C血症患病情况无明显相关性。②糖代谢状态与血清学生化指标的关系：IGT和DM组与糖代谢正常组相比,ALT和AST水平显著性升高(ALT分别升高51.1%和38.5%,AST分别升高29.1%和23.0%);DM组与糖代谢正常组及IFG组相比,Cr水平显著性下降(分别下降了11.0%和13.0%); IGT、IFG+IGT和DM组与糖代谢正常组相比TG水平显著性升高(分别升高了25.7%、29.9%和73.6%),DM组与IGT组相比TG水平显著性升高(升高了38.1%); IGT、IFG+IGT和DM组与糖代谢正常组相比,TC水平显著升高(分别升高了9.5%、8.0%和14.3%)；IGT和DM组与糖代谢正常组相比,LDL-C的水平显著升高(分别升高了14.1%和14.4%)：IFG+IGT组与IGT组相比,HDL-C的水平显著性升高(升高了12.7%)；DM组与糖代谢正常组相比,UA水平显著升高(升高了9.1%)；IGT和DM组与糖代谢正常组相比,HOMA-IR水平显著升高(分别升高了32.6%和71.0%)。
2、血清脂肪细胞因子和肌肉细胞因子的测定结果表明：①HMW-APN浓度在从正常对照组到OB4组是呈逐渐下降趋势的,OB4组浓度是正常对照组的60.2%,差异具有显著性,说明随着糖代谢状况的恶化,保护性脂肪细胞因子HMW-APN的水平逐渐降低。女性的HMW-APN浓度在各组中都是明显高于男性的；在男性和女性中,HDL-C与HMW-APN浓度呈正相关,体脂、BMI、ALT、FINS、LDL-C和HOMA-IR与HMW-APN浓度呈负相关；在女性中还有AST、TG和TC与HMW-APN浓度呈负相关。②GPC-4的浓度从正常对照组到OB4组呈升高趋势,OB4组浓度是正常对照组的1.36倍；且在男性和女性中浓度不一,除了在OB1组男性GPC-4浓度略低于女性外(无显著性差异),各组均是男性GPC-4水平高于女性；在男性和女性中,BMI、ALT、AST、FINS和HOMA-IR与GPC-4浓度呈正相关；在男性中还有体脂、TC和LDL-C与GPC-4浓度呈正相关,年龄和HDL-C与GPC-4浓度呈负相关；③TNF-α在各组之间浓度无显著性差异,在男性和女性中,BMI、FINS和HOMA-IR与TNF-α浓度呈正相关,HDL-C与TNF-α浓度呈负相关；在女性中还有年龄与TNF-α浓度呈显著正相关。④Irisin在OB3和OB4组浓度高于其它组,且在男性中与年龄呈负相关(均以P<0.05为有统计学差异)。
结论：
与糖代谢正常的人群相比,糖耐量受损患者更易合并高血压和高脂血症。随着糖代谢状况的恶化,血清保护性脂肪细胞因子HMW-APN的浓度逐渐降低；而炎性因子TNF-α的水平没有显著改变；新型脂肪细胞因子GPC-4和新型肌肉细胞因子Irisin的浓度均出现逐渐升高的趋势；提示这些新型的细胞因子通过增加自身的水平抑制TNF-α等炎性因子的分泌,试图延缓糖代谢状况恶化的进程。
Object:
Now obesity is an important disease that threats public health, sharp increases in the prevalence of obesity have occurred worldwide, especially in China. Obese patients are at risk for developing coronary heart disease, hypertension, type2diabetes, dyslipidemia, sleep apnea et al. The aim of this study is to investigate the morbidity and the condition of complications of obesity.
Method:
We retrospectively analyze the clinical data of552patients who have been diagnosed simple obesity from2000to2013in the endocrinology department of Peking Union Medical Colledge Hospital. We design an access database, and then we analyze the association between the prevalence of hypertension, hyperlipidemia, impaired glucose tolerance, irregular menses et al with body mass index (BMI) of the obese patients using statistical methods.
Results:
1. The mean age of the552obese patients is26.3±13.0years of age, and the mean BMI is35.57±6.87kg/m2. Totally there are200male patients and352female patients.
2. There are155minors among the552patients, with a mean age of14.1±2.4,76of which are male and79are female. One hundred and ten minors are brought into statistical analysis,45of which are male and65are female. The results of the statistical analysis are:In minor male, the prevalence of hypertension is44.2%, and is not correlated with BMI, with the P value=0.50. In minor female, the prevalence of hypertension is58.3%, and is positively correlated with body mass index (BMI), with the P value=0.008, OR=4.62and95%confidence interval [1.35-17.92]. Creatinine (Cr), hypersensitive C reactive protein (hsCRP) and homeostasis model assessment of insulin resistance index (HOMA-IR) are positively correlated with BMI, and free thyroxine (FT4) is negatively correlated with BMI.
3. In all397adults are brought into statistical analysis, in which there are124male and273female. The results of the statistical analysis are:①In male adults, the incidence of hypertension is50.4%, and is correlated with BMI, with the P values<0.001. The prevalence of low HDL-C is52.7%, and is correlated with BMI, with the P value=0.02. And the prevalence of metabolic syndrome is60.3%, and is correlated with BMI, with the P value<0.001. However the incidence of hyperlipidemia, T2DM, fatty liver and OSAS are not correlated with BMI, with the P value=0.62,0.21,0.66and0.13, respectively.②In female adults, the incidence of hypertension is31.2%, and is correlated with BMI, with the P values=0.002. However the prevalence of low high density lipoprotein cholesterol (HDL-C) is23.2%, and is correlated with BMI, with the P value=0.005. The incidence of type2diabetes mellitus (T2DM) is14.3%, and is correlated with BMI, with the P value=0.03. And the incidence of fatty liver is correlated with BMI, with the P value=0.004. The prevalence of metabolic syndrome is69.9%, and is correlated with BMI, with the P value=0.04. The prevalence of obstructive sleep apnea syndrome (OSAS) is94.8%, and the BMI of the sick group of OSAS is markedly higher than normal group, with the P value=0.007.③For women between18and45years of reproductive age, BMI is positively correlated with irregular menses, with the P value=0.02.④In male and female adults, direct bilirubin (DBil), uric acid (UA), hsCRP, fasting blood glucose (FBG), fasting insulin (FINS) and HOMA-IR are positively correlated with BMI, and albumin (Alb), Cr, HDL-C, apolipoproteinB (ApoB) and testosterone (T) are negatively correlated with BMI. While in female adults, alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), total bilirubin (TBil), free fatty acid (FFA) and triiodothyronine (T3) are positively correlated with BMI.
Conclusion:
To sum up, we find that in simple obese minors, the prevalence of hypertension is higher and is positively correlated with BMI. In simple obese male adults, hypertension, low HDL-C and metabolic syndrome are positively correlated with BMI. And despite hypertension, low HDL-C and metabolic syndrome, type2diabetes mellitus, fatty liver are also positively correlated with BMI in simple obese female adults.
Object:
In obese patients, the prevalence of type2diabetes mellitus, impaired glucose tolerance and insulin resistance is sharp increased compared with normal weight people. The serum levels of certain adipokines and muscle factors may play an important role in it. Our study tries to investigate the relationship between changes of serum adipokines and muscle factor levels and obesity-related metabolic factors. The adipokines in our study include high-molecular-weight adiponectin, glypican-4, tumor necrosis factor-a and the muscle factor refers to irisin.
Method:
We select1146clinical cases from endocrinology department of Peking Union Medical College Hospital and do the statistical analysis. We analyze the relationship between the glucose metabolism status and several serum factors. All patients being analyzed are adults and have3hour oral glucose tolerance test (OGTT) results. All patients have exact diagnosis of their glucose metabolism status.413men and715women are included. Then we select208testees and divide them into5groups:normal control group (patients with normal glucose tolerance, normal insulin level and normal weight), OBI group (obese patients with normal glucose tolerance and normal insulin level), OB2group (obese patients with normal glucose tolerance but high insulin level), OB3group (obese patients with impaired glucose tolerance [IGT]) and OB4group (obese patients with type2diabetes mellitus [DM]). There are totally38patients in normal control group,40in OBI group,39in OB2group,50in OB4group and41in OB4group. Each one of the five groups has no statistical difference of age and sex composition with every other group. We use their fasting serum sample in the test. Since there are three reagent kits in total, for quality control's sake, we select one37-years-old male control and add his serum sample on all three kits (once for each kit). So there are210samples in total and300μl for each. Then we use enzyme-linked immunosorbent assay (ELISA) to test the level of irisin, TNF-a, glypican-4and HMW-APN of the serum sample.
Results:
1. The results of the cases analysis:①Compared with normal glucose metabolism (NGM) people, patients in the impaired glucose tolerance (IGT) group and type2diabetes mellitus (DM) group are more likely to combine hypertension. Patients in the IGT, DM, and impaired fasting glucose (IFG)+IGT group are more likely to combine hyperlipidemia as compared with NGM people. Meanwhile the incidence of low HDL-C is not correlated with glucose metabolism status.②For the serum factors, the level of ALT and AST are markedly higher in IGT and DM patients compared with NGM people (elevated51.1%and38.5%for AST, and29.1%and23.0%for AST). Compared with NGM people and IFG patients, patients in DM group have markedly lower Cr level (decreased11.0%and13.0%, separately). Patients in IGT, DM, and IFG+IGT group have markedly higher TG level compared with NGM people(elevated25.7%,29.9%and73.6%, separately), and patients in DM group have markedly higher TG level compared with the patients in IGT group (elevated38.1%). At the same time, patients in IGT, DM, and IFG+IGT group have markedly higher TC serum level compared with NGM people (elevated9.5%,8.0%and14.3%, separately). Compared with NGM people, patients in IGT and DM group have markedly higher LDL-C level (elevated14.1%and14.4%, separately). Patients in IFG+IGT group have markedly higher HDL-C level compared with IGT group (elevated12.7%). Compared with NGM people, patients in DM group have markedly higher UA level (elevated9.1%). Meanwhile patients in IGT and DM group have markedly higher HOMA-IR level compared with NGM people (elevated32.6%and71.0%, separately).
2. The results of the four serum factors:①The levels of HMW-APN trend down from normal control group (NOR) to OB4group, the level of HMW-APN in OB4group is only60.2%of that of NOR, and the level of HMW-APN is clearly higher in female than in male. In male and female, HDL-C is positively correlated with the level of HMW-APN, while body fat, BMI, ALT, FINS, LDL-C and HOMA-IR are negatively correlated with the level of HMW-APN. While in female, AST, TG and TC are negatively correlated with the level of HMW-APN.②From NOR to OB4group, the levels of GPC-4trend up. The level of GPC-4in OB4group is1.36fold larger than that of NOR. The levels of GPC-4are different in male and female; whereas it is a little bit lower in male than in female in group1(there is no statistical significance), the levels of GPC-4in male are higher than that in female in all the other groups. In male and female, BMI, ALT, AST, FINS and HOMA-IR are positively correlated with the level of GPC-4, while in male, body fat, TC and LDL-C are positively correlated with the level of GPC-4, and age is negatively correlated with the level of GPC-4.③There are no statistical differences between the levels of TNF-a in different groups. In male and female, BMI, FINS and HOMA-IR are positively correlated with the level of TNF-α, and the level of HDL-C is negatively correlated with the level of TNF-a. While in female, age is markedly positively correlated with the level of TNF-a.④The level of irisin is higher in patients of OB3and OB4groups than other groups, and in male age is markedly negatively correlated with the level of irisin (P<0.05).
Conclusion:
Compared with normal glucose metabolism people, patients with impaired glucose tolerance are more likely to combine hypertension and hyperlipidemia. As the glucose metabolism status goes worse, the level of the protective adipokine HMW-APN trends down, meanwhile there are no statistical significances between the levels of the inflammatory factor TNF-a. However the levels of the new adipokine GPC-4and the new muscle factor Irisin trends up, indicating that these new cytokines depress the secretion of inflammatory factors like TNF-a and try to delay the exacerbation process of glucose metabolism status.
引文
[1]Visscher TL, Seidell JC. The public health impact of obesity [J]. Annu Rev Public Health 2001,22: 355-375.
[2]武阳丰,马冠生,胡永华,等.中国居民的超重和肥胖流行现状[J].中国预防医学杂志,2005,39(5)：316-320.
[3]丁宗一.1986-1996年儿童期单纯肥胖症研究[J].中华儿科杂志,1998,36(7)：404-407.
[4]中国肥胖问题工作组数据汇总分析协作组,我国成人体重指数和腰围对相关疾病危险因素异常的预测价值：适宜体重指数和腰围切点的研究[J].中华流行病学杂志,2002,23(1)：5-10.
[5]Louis JA. Classification of obesity and assessment of obesity-related health risks [J]. Obetity Research,2002,10(2):105S-115S.
[6]国际生命科学学会中国办事处中国肥胖问题工作组.中国成人体质指数分类的推荐意见简介[J].中华预防医学杂志.2001；35(5)：349-350.
[7]中国肥胖问题工作组数据汇总分析协作组.我国成人体重指数和腰围对相关疾病危险因素异常的预测价值：适宜体重指数和腰围切点的研究[J].中华流行病学杂志.2002；23(1)：5-10.
[8]中国肥胖问题工作组.中国学龄儿童青少年超重、肥胖筛查体重指数值分类标准[J].中华流行病学杂志,2004,25(2)：97-102.
[9]William J Klish, Definition; epidemiology; and etiology of obesity in children and adolescents. www.uptodate.com 2013;May 14.
[10]席波,米杰,王俐,等.北京市儿童青少年原发性高血压的家庭聚集性分析[J].中华流行病学杂志.2008；29(9)：849-854.
[11]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-411.
[12]《中华儿科杂志》编辑委员会.儿童青少年血脂异常防治专家共识[J].中华儿科杂志,2009,47(6)：426-428.
[13]The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care.1997; 20:1183-1197.
[14]Katsuki A SY, Gabazza EC, Murashima S, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care. 2001; 24:362-365.
[15]Asasco JF, Pardo S, Real JT, et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26:3320-3325.
[16]Friedemann C, Heneghan C, Mahtani K, et al. Cardiovascular disease risk in healthy children and its association with body mass index:systematic review and meta-analysis. BMJ 2012; 345:e4759.
[17]Sorof J, Daniels S. Obesity hypertension in children:a problem of epidemic proportions. Hypertension 2002; 10(40):441-447.
[18]Maggio AB, Aggoun Y, Marchand LM, et al. Associations among obesity, blood pressure, and left ventricular mass. J Pediatr 2008; 152(4):489-493.
[19]Sun SS, Grave GD, Siervogel RM, et al. Systolic blood pressure in childhood predicts hypertension and metabolic syndrome later in life. Pediatrics 2007; 119(2):237-246.
[20]Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med 2011; 365(20):1876-1885.
[21]Harel Z, Riggs S, Vaz R, et al. Isolated low HDL cholesterol emerges as the most common lipid abnormality among obese adolescents. Clin Pediatr (Phila) 2010; 49(l):29-34.
[22]Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics 2011; 128(Supplement 5):S213-256.
[23]LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990; 81(5):1721-1733.
[24]Robert S Rosenson. Screening guidelines for dyslipidemia. www.uptodate.com 2013; April.
[25]William J Klish. Comorbidities and complications of obesity in children and adolescents. www.uptodate.com 2012; Aug.
[26]Klop B., Castro Cabezas M. Chylomicrons:A key biomarker and risk factor for cardiovascular disease and for the understanding of obesity. Curr. Cardiovasc. Risk. Rep.2012; 6:27-34.
[27]Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002; 346(11):802-810.
[28]Hannon TS, Rao G, Arslanian SA. Childhood obesity and type 2 diabetes mellitus. Pediatrics 2005; 116(2):473-480.
[29]Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes:the TODAY cohort at baseline. J Clin Endocrinol Metab 2011; 96(1):159-167.
[30]Tirosh A, Shai I, Afek A, et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med 2011; 364(14):1315-1325.
[31]Skinner AC, Steiner MJ, Henderson FW, et al. Multiple markers of inflammation and weight status:cross-sectional analyses throughout childhood. Pediatrics 2010; 125(4):e801-809.
[32]Wang C, Yatsuya H, Tamakoshi K, et al. Positive association between high sensitivity C-reactive protein and incidence of type-2 diabetes mellitus in Japanese workers:6-year follow-up. Diabetes Metab Res Rev 2013; Mar 6.
[33]Cari MK, Eizabeth AP, Paul WL, et al. Body fatness and markers of thyroid function among U.S. men and women. PloS One 2012; 7(4):e34979.
[34]Chen H, Zhang H, Tang W. Thyroid function and morphology in overweight and obese children and adolescents in a Chinese population. J Pediatr Endocrinol Metab.2013; 26(5-6):489-496.
[35]Reinehr T, Isa A, De Sousa G, et al. Thyroid hormones and their relation to weight status. Horm Res 2008; 70:51-57.
[36]Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk:the Framingham experience. Arch Intern Med 2002; 162(16):1867-1872.
[37]Gentile CL et al. Cardiorespiratory fitness influences the blood pressure response to experimental weight gain. Obesity (Silver Spring) 2007; 15:3005-3012.
[38]Neter JE et al. Influence of weight reduction on blood pressure:a meta-analysis of randomized combined trials. Hypertension 2003; 42:878-884.
[39]Horvath K et al. Long-term effects of weight reducing interventions in hypertensive patients: systematic review and meta-analysis. Arch Intern Med 2008; 168:571-580.
[40]Stevens VJ et al. Long-term weight loss and changes in blood pressure:results of the Trials of Hypertension Prevention, phase II. Arch Intern Med 2001; 134:1-11.
[41]Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease:pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006; 26(5):968-976.
[42]Robert SR. Screening guidelines for dyslipidemia. www.uptodate.com 2013;Apr.
[43]Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95(1):69-75.
[44]Vidar Hjellvik, Solveig Sakshaug, Hanne Str(?)em. Body mass index, triglycerides, glucose, and blood pressure as predictors of type 2 diabetes in a middle-aged Norwegian cohort of men and women. Clinical Epidemiology 2012; 4:213-224.
[45]Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341(6): 427-434.
[46]Speiser PW, Rudolf MC, Anhalt H, et al. Childhood obesity. J Clin Endocrinol Metab 2005; 90(3):1871-1887.
[47]Mandato C, Lucariello S, Licenziati MR, et al. Metabolic, hormonal, oxidative, and inflammatory factors in pediatric obesity-related liver disease. J Pediatr 2005; 147(1):62-66.
[48]Chen K, Lindsey JB, Khera A, et al.Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis:observations from the Dallas Heart Study. Diab Vasc Dis Res 2008; 5(2):96-101.
[49]Gao W, DECODE Study Group. Does the constellation of risk factors with and without abdominal adiposity associate with different cardiovascular mortality risk? Int J Obes 2008; 32(5):757-762.
[50]Ilanne-Parikka P, Eriksson JG, Lindstrom J, et al. Finnish Diabetes Prevention Study Group. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care 2008; 31(4):805-807.
[51]Phelan S, Wadden TA, Berkowitz RI, et al. Impact of weight loss on the metabolic syndrome. Int J Obes 2007; 31:1442-1448.
[52]Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000; 284(23):3015-3021.
[53]Newman AB, Foster G, Givelber R, Nieto FJ, Redline S, Young T. Progression and regression of sleep-disordered breathing with changes in weight:the Sleep Heart Health Study. Arch Intern Med 2005; 165(20):2408-2413.
[54]Grunstein RR, Stenlof K, Hedner JA, et al. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep 2007;30(6):703-710.
[55]B.K.Jacobsen, S.F.Knutsen, K.Oda, et al. Obesity at age 20 and the risk of miscarriages, irregular periods and reported problems of becoming pregnant:the Adventist Health Study-2. Eur J Epidemiol 2012; 27:923-931.
[56]Wei S, Schmidt MD, Dwyer T. Obesity and menstrual irregularity:associations with SHBG, testosterone, and insulin. Obesity (Silver Spring).2009 May; 17(5):1070-1076.
[57]陈维真,朱康顺,罗辉.青少年肥胖女性血清睾酮与代谢综合征的关系[J].当代医学2010；9：55-57.
[58]Jenko-Praznikar Z, Petelin A, Jurdana M, et al. Serum bilirubin levels are lower in overweight asymptomatic middle-aged adults:An early indicator of metabolic syndrome?, Metabolism 2013, http://dx.doi.org/10.1016/j.metabol.2013.01.011.
[59]Wu Y, Li M, Xu M, et al. Low serum total bilirubin concentrations are associated with increased prevalence of metabolic syndrome in Chinese. J Diabetes 2011; 3:217-224.
[60]S.H. Choi, K.E. Yun, H.J. Choi. Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults. Nutrition, Metabolism & Cardiovascular Diseases 2013; 23:31-37.
[61]De Miguel E, Puig JG, Castillio C, et al. Diagnosis of gout in patients with asymptomatic hyperuricaemia:a pilot ultrasound study. Ann Rheum Dis 2012; 71(1):157-158.
[62]Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med.2007; 120:442-447.
[63]Nannipieri M, Cecchetti F, Anselmino M, et al. Expression of thyrotropin and thyroid hormone receptors in adipose tissue of patient with morbid obesity and/or type 2 diabetes:effects of weight loss. Int J Obes (Lond) 2009;33:1001-1006. Epub 2009 Jul 28.
[64]Reinehr T. Obesity and thyroid function. Mol Cell Endocrinol 2010; 316:165-171.
[65]Garten A., Schuster S.& Kiess W. The insulin-like growth factors in adipogenesis and obesity. Endocrinol. Metab. Clin. North Am.2012; 41:283-295.
[66]Cartwright, M. J. et al. Aging, depot origin, and preadipocyte gene expression. J. Gerontol. A. Biol. Sci. Med. Sci.2010; 65:242-251.
[67]Chen PH, Chen JD, Lin YC. A better parameter in predicting insulin resistance:Obesity plus elevated alanine aminotransferase. World J Gastroenterol 2009; 15(44):5598-5603.
[68]Roden M., Price T.B., Perseghin G., Petersen, K.F., et al. Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Invest.1996; 97:2859-2865.
[69]McQuaid S.E., Hodson L., Neville M.J., et al. Downregulation of adipose tissue fatty acid trafficking in obesity:A driver for ectopic fat deposition? Diabetes 2011; 60:47-55.
[70]Jon O.E., Michael D.J. Fat depots, free fatty acids, and dyslipidemia. Nutrients 2013; 5:498-508.
[71]Fernando Gerchman, Jenny Tong, Kristina M. Utzschneider, et al. Body mass index is associated with increased creatinine clearance by a mechanism independent of body fat distribution. J Clin Endocrinol Metab.2009; 94(10):3781-3788.
[72]Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes 2010; 17: 224-232.
[73]MacDonald AA, Herbison GP, Showell M, Farquhar CM. The impact of body mass index on semen parameters and reproductive hormones in human males:a systematic review with meta-analysis. Hum Reprod Update 2010; 16:293-311.
[74]Brand JS, van der Tweel I, Grobbee DE, et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome:a systematic review and meta-analysis of observational studies. Int J Epidemiol 2011; 40:189-207.
[75]Laaksonen DE, Niskanen L, Punnonen K, et al. Themetabolic syndrome and smoking in relation to hypogonadism in middle-aged men:a prospective cohort study. J Clin Endocrinol Metab 2005; 90:712-719.
[76]Sandeep D, Michael GM, Cecilia LM, et al. Testosterone concentrations in disbetic and nondiabetic obese men. Diabetes Care 2010; 33(6):1186-1192.
[1]Hirose H, Yamamoto Y, Seino-Yoshihara Y, et al. Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders. J Atheroscler Thromb,2010,17:1201-1211.
[2]Menzaghi C, Salvemini L, Paroni G, et al. Circulating high molecular weight adiponectin isoform is heritable and shares a common genetic background with insulin resistance in nondiabetic White Caucasians from Italy:evidence from a family-based study. J Intern Med,2010,267:287-294.
[3]Isao Saito, Kazumasa Yamagishi, Choy-Lye Chei, et al. Total and high molecular weight adiponectin levels and risk of cardiovascular disease in individuals with high blood glucose levels. Atherosclerosis 2013.04.014.
[4]Ussar S, Bezy O, Bliiher M. Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine. Diabetes,2012 Sep; 61(9):2289-2298.
[5]Gesta S, Bluher M, Yamamoto Y, et al. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Natl Acad Sci USA,2006; 103:6676-6681.
[6]Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010; 314:1-16.
[7]Bostrom P, Wu J, Jedrychowski MP, et al. A PGCl-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature,2012,481:463-468.
[8]The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care.1997; 20:1183-1197.
[9]Cheung BM. The hypertension-diabetes continuum. J Cardiovasc Pharmacol.2010; 55:333-539.
[10]Landsberg L,MolitchM. Diabetes and hypertension:pathogenesis, prevention and treatment. Clin Exp Hypertens.2004; 26:621-628.
[11]Mugo MN, Stump CS, Rao PG, et al. Hypertension and diabetes mellitus. In:Black HR, Elliott WJ, editors. Hypertension:A Companion to Braunwald's Heart Disease. Elsevier; 2007:409.
[12]Mazzone, T., Chait, A.& Plutzky, J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008; 371:1800-1809.
[13]Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52(2):453-462.
[14]ACCORD Study Group et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med.2010; 362:1563-1574.
[15]Farmer JA. Diabetic dyslipidemia and atherosclerosis:evidence from clinical trials. Curr Diab Rep 2008 Feb; 8(1):71-77.
[16]D. John Betteridge. Lipid control in patients with diabetes mellitus. Nature Reviews Cardiology 2011; 8:278-290.
[17]Salmela PI, Sotaniemi EA, Niemi M, Maentausta O. Liver function tests in diabetic patients. Diabetes Care 1984; 7:248-254.
[18]Meltzer AA, Everhart JE. Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans. Am J Epidemiol 1997; 146:565-571.
[19]Targher G, Bertolini L, Padovani R, Rodella S, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care.2007; 30:1212-1218.
[20]Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98:960-967.
[21]Westerbacka J, Corner A, Tiikkainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women:implications for sex differences in markers of cardiovascular risk. Diabetologia 2004; 47:1360-1369.
[22]Wannamethee SG, Shaper AG, Lennon L, et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005; 28:2913-2918.
[23]Ioannou GN, Weiss NS, Boyko EJ, et al. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 2005; 128:627-635.
[24]Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98:960-967.
[25]H.E. Resnick, G.L. Foster, J. Bardsley, R.E. Ratner, Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes,1999-2002:the National Health and Nutrition Examination Survey, Diabetes Care 2006; 29:531-537.
[26]R.B. D'Agostino Jr., R.F. Hamman, A.J. Karter, et al. Cardiovascular disease risk factors predict the development of type 2 diabetes:the insulin resistance atherosclerosis study, Diabetes Care 2004; 27:2234-2240.
[27]J.P. Despres,1. Lemieux, Abdominal obesity and metabolic syndrome, Nature 2006; 444: 881-887.
[28]H.N. Ginsberg, Y.L. Zhang, A. Hernandez-Ono. Metabolic syndrome:focus on dyslipidemia, Obesity (Silver Spring) 2006; 14 (Suppl.1):41S-49S.
[29]Diabetes Obesity Center of Excellence. Hypertriglyceridemia secondary to obesity and diabetes. Biochimica et Biophysica Acta 2012; 1821:819-825.
[30]Kannel WB. Lipids, diabetes, and coronary heart disease:insights from the Framingham Study. Am Heart J 1985;110:1100-1107.
[31]Asia Pacific Cohort Studies Collaboration. Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific resion. Diabetologia 2007; 50:2289-2297.
[32]Turner, R. C. et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus:United Kingdom Prospective Diabetes Study (UKPDS:23). BMJ 1998; 316:823-828.
[33]Howard BV, Robbins DC, Sievers ML, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL:the Strong Heart Study. Arterioscler Thromb Vasc Biol 2000 Mar; 20(3):830-835.
[34]Peter H, Peter R, Richard JJ, et al. Serum uric acid as a new player in the development of diabetic nephropathy. Journal of Renal Nutrition 2011; 21(1):124-127.
[35]United States Renal Data System. Available at:www.usrds.org.2008.
[36]Parving H-H, Mauer M, Ritz E. Diabetic nephropathy. In:Brenner BM (ed.):Brenner & Rector's The Kidney,8th ed. Boston, MA:WB Saunders,2008, pp 1265-1298.
[37]Perlstein TS, Gumieniak O, Hopkins PN, et al. Uric acid and the state of the intrarenal renin-angiotensin systemin humans. Kidney Int 2004; 66:1465-1470.
[38]Hovind P, Rossing P, Tarnow L, et al. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetesf an inception cohort study. Diabetes 2009; 58:1668-1671.
[39]Jalal DI, Rivard CJ, Johnson RJ, et al. Serumuric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes:findings from the coronary artery calcification in type 1 diabetes study. Nephrol Dial Transplant 2010; 25:1865-1869.
[40]Rosolowsky ET, Ficociello LH, Maselli NJ, et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2008; 3:706-713.
[41]Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment:insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
[42]Zhu N, Pankow JS, Ballantyne CM, et al. High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. J Clin Endocrinol Metab 2010; 95:5097-5104.
[43]Bluher S, Ziotopoulou M, Bullen JW Jr, et al. Responsiveness to peripherally administered melanocortins in lean and obese mice. Diabetes 2004; 53:82-90.
[44]Li S, Shin JJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes:a systematic review and meta-analysis. JAMA 2009; 302:179-188.
[45]Schulze MB, Shai I, Rimm EB, et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54:534-539.
[46]Cnop M, Utzschneider KM, Carr DB, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins:evidence for independent roles of age and sex. Diabetologia 2003; 46:459-469.
[47]Yoo HJ, Hwang SY, Cho GJ,et al. Association of glypican-4 with body fat distribution, insulin resistance, and non-alcoholic fatty liver disease. J Clin Endocrinol Metab.2013 Apr 30. [Epub ahead of print].
[48]Yeon-Kyung Choi, Mi-Kyung Kim, Kwi Hyun Bae, et al. Serum irisin levels in new-onset type 2 diabetes[J]. Diabetes Research and Clinical Practice,2012,100:96-101.
[49]Zhang HJ, Zhang XF, Ma ZM, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults[J]. J Hepatol,2013 May 8.
[50]Cunha A. Basic research:Irisin—behind the benefits of exercise. Nat Rev Endocrinol,2012; 8(4): 195.
[51]Andreas S, Tobias H, Miriam GS, et al. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity-Correlation with body mass index. Peptides 2013; 39: 125-130.
[52]Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans:I. Predictors of circulating concentrations in serum and plasma and Ⅱ. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61:1725-1738.
[53]卢东晖,张帆,阴慧清.2型糖尿病胰岛素抵抗与TNF-α、肥胖的关系[J].中华全科医学,2008,11(6)：1113-1114.
[54]Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010;316,129-139.
[1]中国肥胖问题工作组,中国学龄儿童青少年超重、肥胖筛查体重指数值分类标准[J].中华流行病学杂志,2004,25(2)：97-102.
[2]中国肥胖问题工作组数据汇总分析协作组.我国成人体重指数和腰围对相关疾病危险因素异常的预测价值：适宜体重指数和腰围切点的研究[J].中华流行病学杂志,2002,23(1)：5-10.
[3]Louis JA. Classification of obesity and assessment of obesity-related health risks[J]. Obetity Research,2002,10(2):105S-115S.
[4]赵青,张抒扬.肥胖症与心血管疾病[J].中国医学科学院学报,2012,34(4)：431-436.
[5]Rocha VZ, Floco EJ. Inflammatory concepts of obesity[J]. Int J Inflam,2011,2011:529061.
[6]Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002; 346:802.
[7]Vidar Hjellvik, Solveig Sakshaug, Hanne Strom. Body mass index, triglycerides, glucose, and blood pressure as predictors of type 2 diabetes in a middle-aged Norwegian cohort of men and women. Clinical Epidemiology 2012; 4:213-224.
[8]Robyn J, Daniel J, Jonathan E, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care,2003,26:1731-1737.
[9]Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men:impact on cardiovascular disease and diabetes. J Epidemiol Community Health 2005; 59(2):134-139.
[10]Fujimoto WY, Jablonski KA, Bray GA, et al. Diabetes Prevention Program Research Group. Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes 2007; 56(6):1680-1685.
[11]Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA 2009; 302:401-411.
[12]Doll S, Paccaud F, Bovet P, Burnier M, Wietlisbach V. Body mass index, abdominal adiposity and blood pressure:consistency of their association across developing and developed countries. Int J Obes Relat Metab Disord 2002; 26:48-57.
[13]Sorof J, Daniels S. Obesity hypertension in children:a problem of epidemic proportions. Hypertension 2002; 40:441.
[14]Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk:the Framingham experience. Arch Intern Med 2002; 162:1867.
[15]Sun Z, Zheng L, Detrano R, et al. Risk of progression to hypertension in a rural Chinese women population with prehypertension and normal blood pressure. Am J Hypertens 2010; 23:627-632.
[16]陈纪春,段秀芳,黄广勇等.体重指数与不同亚型高血压的关系[J].高血压杂志,2006,6(14)：432-435.
[17]Mancia G, De BG, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension(ESH) and of the European Society of Cardiology(ESC). J Hypertens 2007; 25: 1105-1187.
[18]SjostromL, NarbroK, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741-752.
[19]Siebenhofer A, Horvath K, Jeitler K, et al. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev 2009; Jul 8:CD007654.
[20]Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease:pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006; 26:968.
[21]Harel Z, Riggs S, Vaz R, et al. Isolated low HDL cholesterol emerges as the most common lipid abnormality among obese adolescents. Clin Pediatr (Phila) 2010; 49:29.
[22]Lauer RM, Lee J, Clarke WR. Factors affecting the relationship between childhood and adult cholesterol levels:the Muscatine Study. Pediatrics 1988; 82:309-318.
[23]Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk:the Framingham experience. Arch Intern Med 2002; 162(16): 1867-1872.
[24]Fox CS, Pencina MJ, Wilson PW, et al. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care 2008;31(8):1582-1584.
[25]Iribarren C, Darbinian JA, Lo JC, et al. Value of the sagittal abdominal diameter in coronary heart disease risk assessment:cohort study in a large, multiethnic population. Am J Epidemiol 2006;164:1150.
[26]McGill HC Jr, McMahan CA, Herderick EE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002; 105:2712.
[27]Madala MC, Franklin BA, Chen AY, et al. Obesity and age of first non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2008; 52:979.
[29]Chen K, Lindsey JB, Khera A, et al. Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis:observations from the Dallas Heart Study. Diab Vasc Dis Res 2008;5(2):96-101.
[30]Ilanne-Parikka P, Eriksson JG, Lindstrom J, et al. Finnish Diabetes Prevention Study Group. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care 2008;31(4):805-807.
[31]Phelan S, Wadden TA, Berkowitz RI, et al. Impact of weight loss on the metabolic syndrome. Int J Obes 2007;31:1442-1448.
[32]Foster GD, Sanders MH, Millman R, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care 2009; 32:1017.
[33]Verhulst SL, Schrauwen N, Haentjens D, et al. Sleep-disordered breathing in overweight and obese children and adolescents:prevalence, characteristics and the role of fat distribution. Arch Dis Child 2007; 92:205.
[34]Resta O, Foschino-Barbaro MP, Legari G, et al. Sleep-related breathing disorders, loud snoring and excessive daytime sleepiness in obese subjects. Int J Obes Relat Metab Disord 2001;25(5):669-675.
[35]Pillar G, Shehadeh N. Abdominal fat and sleep apnea:the chicken or the egg? Diabetes Care 2008;31(suppl 2):S303-S309.
[36]Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000;284(23):3015-3021.
[37]Grunstein RR, Stenlof K, Hedner JA, Peltonen M, Karason K, Sjostrom L. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep 2007;30(6):703-710.
[38]Linnemann B, Zgouras D, Schindewolf M et al. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism:results from the German MAISTHRO Registry. Blood Coagul Fibrinolysis 2008; 19:159-165.
[39]Kabrhel C, Varraso R, Goldhaber SZ, Rimm EB. Prospective study of BMI and the risk of pulmonary embolism in women. Obesity 2009; 17(11):2040-2046.
[40]Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005; 118(9):978-980.
[41]Eichinger S, Hron G, Bialonczyk C, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008.
[42]Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86(1):452-463.
[43]Konstantinides S, Schafer K, Neels JG, Dellas C, Loskutoff DJ. Inhibition of endogenous leptin protects mice from arterial and venous thrombosis. Arterioscler Thromb Vasc Biol 2004;24:2196-2201.
[44]Napoleone E, A DIS, Amore C et al. Leptin induces tissue factor expression in human peripheral blood mononuclear cells:a possible link between obesity and cardiovascular risk? J Thromb Haemost 2007; 5:1462-1468.
[45]Cushman M, Kuller LH, Prentice R et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292:1573-1580.
[46]Speiser PW, Rudolf MC, Anhalt H, et al. Childhood obesity. J Clin Endocrinol Metab 2005; 90:1871.
[47]Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of non-alcoholic fatty liver disease in children:a follow-up study for up to 20 years. Gut 2009; 58:1538.
[48]Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191(2):235-240.
[49]Riquelme A, Arrese M, Soza A, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 2009; 29(1):82-88.
[50]Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006; 26(7):856-863.
[51]Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006; 82(967):315-322.
[51]Liu B, Balkwill A, Spencer E, Beral V, Million Women Study Collaborators. Relationship between body mass index and length of hospital stay for gallbladder disease. J Public Health (Oxf)2008;30(2):161-166.
[52]Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr 2004;80(1):38-44.
[53]Ehrmann DA. Polycystie ovary syndrome. N Engl J Med,2005,352:1223-1236.
[54]Mehrabian F, Khani B, Kelishadi R, Ghanbari E. The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria. Endokrynol Pol 2011; 62:238-242.
[55]Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93:162-168.
[56]Balen AH, Conway GS, Kaltsas G et al. Polycystic ovary syndrome:the spectrum of the disorder in 1741 patients. Hum Reprod 1995; 10:2107-2111.
[57]Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome:relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf) 1994; 41:463-471.
[58]Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:48-53.
[59]Himelein MJ, Thatcher SS. Depression and body image among women with polycystic ovary syndrome. J Health Psychol 2006; 11:613-625.
[60]Barry JA, Kuczmierczyk AR, Hardiman PJ. Anxiety and depression in polycystic ovary syndrome:a systematic review and meta-analysis. Hum Reprod 2011; 26:2442-2451.
[61]Weiner CL, Primeau M, Ehrmann DA. Androgens and mood dysfunction in women:comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med 2004; 66: 356-362.
[62]Rasgon NL, Rao RC, Hwang S et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord 2003; 74:299-304.
[63]Yucel A, Noyan V, Sagsoz N. The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2006; 126:81-86.
[64]CresswellJL, Barker DJ, Osmond C, et al. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet,1997,350:1131-1135.
[65]Maggard MA, Yermilov I, Li Z, et al. Pregnancy and fertility following bariatric surgery:a systematic review. JAMA 2008; 300:2286.
[66]Sallmen M, Sandier DP, Hoppin JA, et al. Reduced fertility among overweight and obese men. Epidemiology 2006; 17:520-523.
[67]Swan SH, Elkin EP, Fenster L. The question of declining sperm density revisited:an analysis of 101 studies published 1934-1996. Environ Health Perspect 2000; 108:961-966.
[68]Corona G, Mannucci E, Schulman C, et al. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol 2006; 50:595-604; discussion 604.
[69]Jensen TK, Andersson AM, Jorgensen N, et al. Body mass index in relation to semen quality and reproductive hormones among 1,558 danish men. Fertil Steril 2004; 82:863-870.
[70]Martini AC, Tissera A, Estofan D, et al. Overweight and seminal quality:a study of 794 patients. Fertil Steril 2010; Jan 5.
[71]Smit M, Romijn JC, Wildhagen MF, et al. Sperm chromatin structure is associated with the quality of spermatogenesis in infertile patients. Fertil Steril 2009.
[72]Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ. Association of bioavailable, free, and total testosterone with insulin resistance:influence of sex hormone-binding globulin and body fat. Diabetes Care 2004; 27:861-868.
[73]Niskanen L, Laaksonen DE, Punnonen K, et al. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004; 6:208-215.
[74]Sharman MJ, Volek JS. Weight loss leads to reductions in inflammatory biomarkers after a very-low-carbohydrate diet and a low-fat diet in overweight men. Clin Sci (Lond) 2004; 107: 365-369.
[75]Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105:804-809.
[76]Rexrode KM, Hennekens CH, Willett WC, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997; 277:1539.
[77]Kurth T, Gaziano JM, Berger K, et al. Body mass index and the risk of stroke in men. Arch Intern Med 2002; 162:2557.
[78]Gusrafson B, Hammarstedt a, Andersson CX, et al. Inflamed adipose tissue:a culprit underlying the metabolic syndrome and atherosclerosis[J]. Arterioscler Thromb Vasc Biol,2007,27(11): 2276-2283.
[79]Song YM, Sung J, Davey Smith G, Ebrahim S. Body mass index and ischemic and hemorrhagic stroke:a prospective study in Korean men. Stroke 2004; 35:831-836.
[80]Zhou M, Offer A, Yang G, Smith M, Hui G, Whitlock G et al. Body mass index, blood pressure, and mortality from stroke:a nationally representative prospective study of 212 000 Chinese men. Stroke 2008; 39:753-759.
[81]Pham TM, Fujino Y, Tokui N, Ide R, Kubo T, Shirane K et al. Mortality and risk factors for stroke and its subtypes in a cohort study in Japan. Prev Med 2007; 44:526-530.
[82]Funada S, Shimazu T, Kakizaki M, Kuriyama S, Sato Y, Matsuda-Ohmori K et al. Body mass index and cardiovascular disease mortality in Japan:the Ohsaki study. Prev Med 2008; 47: 66-70.
[83]Calle EE. Obesity and cancer[J]. BMJ,2007;335:1107-1108.
[84]Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity and mortality form cancer in a prospectively studied cohort of US adults[J]. N Engl J Med,2003; 348:1625-1638.
[85]Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer:a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569.
[86]胡红琳.肥胖人群抵抗素表达与血清游离脂肪酸、肿瘤坏死因子、脂联素水平的研究.临床荟萃,2007,22：852-855.
[87]Parker ED, Folsom AR. Intentional weight loss and incidence of obesity-related cancers:the Iowa Womens Health Study. Int J Obes Relat Metab Disord,2003,27(12):1447-1452.
[88]Grotle M, Hagen KB, Natvig B, et al. Obesity and osteoarthritis in knee, hip and/or hand:an epidemiological study in the general population with 10 years follow-up. BMC Musculoskelet Disord 2008; 9:132.
[89]Petry NM, Barry D, Pietrzak RH, Wagner JA. Overweight and obesity are associated with psychiatric disorders:results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med 2008;70(3):288-297.
[90]Strine TW, Mokdad AH, Dube SR, et al. The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults. Gen Hosp Psychiatry 2008;30(2):127-137.
[91]Simon GE, Ludman EJ, Linde JA, et al. Association between obesity and depression in middle-aged women. Gen Hosp Psychiatry 2008;30(1):32-39.
[92]Eisenberg ME, Neumark-Sztainer D, Story M. Associations of weight-based teasing and emotional well-being among adolescents. Arch Pediatr Adolesc Med 2003; 157:733.
[93]Strauss RS. Childhood obesity and self-esteem. Pediatrics 2000; 105:e15.
[94]Becker ES, Margraf J, Turke V, et al. Obesity and mental illness in a representative sample of young women. Int J Obes Relat Metab Disord 2001; 25 Suppl 1:S5.
[95]Erickson SJ, Robinson TN, Haydel KF, Killen JD. Are overweight children unhappy?:Body mass index, depressive symptoms, and overweight concerns in elementary school children. Arch Pediatr Adolesc Med 2000; 154:931.
[96]Staffieri JR. A study of social stereotype of body image in children. J Pers Soc Psychol 1967; 7:101.
[97]Griffiths LJ, Wolke D, Page AS, et al. Obesity and bullying:different effects for boys and girls. Arch Dis Child 2006; 91:121.
[98]Stunkard A, Burt V. Obesity and the body image. Ⅱ. Age at onset of disturbances in the body image. Am J Psychiatry 1967; 123:1443.
[99]Gortmaker SL, Must A, Perrin JM, et al. Social and economic consequences of overweight in adolescence and young adulthood. N Engl J Med 1993; 329:1008.
[100]Sargent JD, Blanchflower DG. Obesity and stature in adolescence and earnings in young adulthood. Analysis of a British birth cohort. Arch Pediatr Adolesc Med 1994; 148:681.
[101]Wang Y. Is obesity associated with early sexual maturation? A comparison of the association in American boys versus girls. Pediatrics 2002; 110:903.
[102]Speiser PW, Rudolf MC, Anhalt H, et al. Childhood obesity. J Clin Endocrinol Metab 2005; 90:1871.
[2]武阳丰,马冠生,胡永华,等.中国居民的超重和肥胖流行现状[J].中国预防医学杂志,2005,39(5)：316-320.
[3]丁宗一.1986-1996年儿童期单纯肥胖症研究[J].中华儿科杂志,1998,36(7)：404-407.
[4]中国肥胖问题工作组数据汇总分析协作组,我国成人体重指数和腰围对相关疾病危险因素异常的预测价值：适宜体重指数和腰围切点的研究[J].中华流行病学杂志,2002,23(1)：5-10.
[5]Louis JA. Classification of obesity and assessment of obesity-related health risks [J]. Obetity Research,2002,10(2):105S-115S.
[6]国际生命科学学会中国办事处中国肥胖问题工作组.中国成人体质指数分类的推荐意见简介[J].中华预防医学杂志.2001；35(5)：349-350.
[7]中国肥胖问题工作组数据汇总分析协作组.我国成人体重指数和腰围对相关疾病危险因素异常的预测价值：适宜体重指数和腰围切点的研究[J].中华流行病学杂志.2002；23(1)：5-10.
[8]中国肥胖问题工作组.中国学龄儿童青少年超重、肥胖筛查体重指数值分类标准[J].中华流行病学杂志,2004,25(2)：97-102.
[9]William J Klish, Definition; epidemiology; and etiology of obesity in children and adolescents. www.uptodate.com 2013;May 14.
[10]席波,米杰,王俐,等.北京市儿童青少年原发性高血压的家庭聚集性分析[J].中华流行病学杂志.2008；29(9)：849-854.
[11]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-411.
[12]《中华儿科杂志》编辑委员会.儿童青少年血脂异常防治专家共识[J].中华儿科杂志,2009,47(6)：426-428.
[13]The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care.1997; 20:1183-1197.
[14]Katsuki A SY, Gabazza EC, Murashima S, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care. 2001; 24:362-365.
[15]Asasco JF, Pardo S, Real JT, et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26:3320-3325.
[16]Friedemann C, Heneghan C, Mahtani K, et al. Cardiovascular disease risk in healthy children and its association with body mass index:systematic review and meta-analysis. BMJ 2012; 345:e4759.
[17]Sorof J, Daniels S. Obesity hypertension in children:a problem of epidemic proportions. Hypertension 2002; 10(40):441-447.
[18]Maggio AB, Aggoun Y, Marchand LM, et al. Associations among obesity, blood pressure, and left ventricular mass. J Pediatr 2008; 152(4):489-493.
[19]Sun SS, Grave GD, Siervogel RM, et al. Systolic blood pressure in childhood predicts hypertension and metabolic syndrome later in life. Pediatrics 2007; 119(2):237-246.
[20]Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med 2011; 365(20):1876-1885.
[21]Harel Z, Riggs S, Vaz R, et al. Isolated low HDL cholesterol emerges as the most common lipid abnormality among obese adolescents. Clin Pediatr (Phila) 2010; 49(l):29-34.
[22]Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics 2011; 128(Supplement 5):S213-256.
[23]LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990; 81(5):1721-1733.
[24]Robert S Rosenson. Screening guidelines for dyslipidemia. www.uptodate.com 2013; April.
[25]William J Klish. Comorbidities and complications of obesity in children and adolescents. www.uptodate.com 2012; Aug.
[26]Klop B., Castro Cabezas M. Chylomicrons:A key biomarker and risk factor for cardiovascular disease and for the understanding of obesity. Curr. Cardiovasc. Risk. Rep.2012; 6:27-34.
[27]Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002; 346(11):802-810.
[28]Hannon TS, Rao G, Arslanian SA. Childhood obesity and type 2 diabetes mellitus. Pediatrics 2005; 116(2):473-480.
[29]Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes:the TODAY cohort at baseline. J Clin Endocrinol Metab 2011; 96(1):159-167.
[30]Tirosh A, Shai I, Afek A, et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med 2011; 364(14):1315-1325.
[31]Skinner AC, Steiner MJ, Henderson FW, et al. Multiple markers of inflammation and weight status:cross-sectional analyses throughout childhood. Pediatrics 2010; 125(4):e801-809.
[32]Wang C, Yatsuya H, Tamakoshi K, et al. Positive association between high sensitivity C-reactive protein and incidence of type-2 diabetes mellitus in Japanese workers:6-year follow-up. Diabetes Metab Res Rev 2013; Mar 6.
[33]Cari MK, Eizabeth AP, Paul WL, et al. Body fatness and markers of thyroid function among U.S. men and women. PloS One 2012; 7(4):e34979.
[34]Chen H, Zhang H, Tang W. Thyroid function and morphology in overweight and obese children and adolescents in a Chinese population. J Pediatr Endocrinol Metab.2013; 26(5-6):489-496.
[35]Reinehr T, Isa A, De Sousa G, et al. Thyroid hormones and their relation to weight status. Horm Res 2008; 70:51-57.
[36]Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk:the Framingham experience. Arch Intern Med 2002; 162(16):1867-1872.
[37]Gentile CL et al. Cardiorespiratory fitness influences the blood pressure response to experimental weight gain. Obesity (Silver Spring) 2007; 15:3005-3012.
[38]Neter JE et al. Influence of weight reduction on blood pressure:a meta-analysis of randomized combined trials. Hypertension 2003; 42:878-884.
[39]Horvath K et al. Long-term effects of weight reducing interventions in hypertensive patients: systematic review and meta-analysis. Arch Intern Med 2008; 168:571-580.
[40]Stevens VJ et al. Long-term weight loss and changes in blood pressure:results of the Trials of Hypertension Prevention, phase II. Arch Intern Med 2001; 134:1-11.
[41]Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease:pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006; 26(5):968-976.
[42]Robert SR. Screening guidelines for dyslipidemia. www.uptodate.com 2013;Apr.
[43]Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95(1):69-75.
[44]Vidar Hjellvik, Solveig Sakshaug, Hanne Str(?)em. Body mass index, triglycerides, glucose, and blood pressure as predictors of type 2 diabetes in a middle-aged Norwegian cohort of men and women. Clinical Epidemiology 2012; 4:213-224.
[45]Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341(6): 427-434.
[46]Speiser PW, Rudolf MC, Anhalt H, et al. Childhood obesity. J Clin Endocrinol Metab 2005; 90(3):1871-1887.
[47]Mandato C, Lucariello S, Licenziati MR, et al. Metabolic, hormonal, oxidative, and inflammatory factors in pediatric obesity-related liver disease. J Pediatr 2005; 147(1):62-66.
[48]Chen K, Lindsey JB, Khera A, et al.Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis:observations from the Dallas Heart Study. Diab Vasc Dis Res 2008; 5(2):96-101.
[49]Gao W, DECODE Study Group. Does the constellation of risk factors with and without abdominal adiposity associate with different cardiovascular mortality risk? Int J Obes 2008; 32(5):757-762.
[50]Ilanne-Parikka P, Eriksson JG, Lindstrom J, et al. Finnish Diabetes Prevention Study Group. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care 2008; 31(4):805-807.
[51]Phelan S, Wadden TA, Berkowitz RI, et al. Impact of weight loss on the metabolic syndrome. Int J Obes 2007; 31:1442-1448.
[52]Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000; 284(23):3015-3021.
[53]Newman AB, Foster G, Givelber R, Nieto FJ, Redline S, Young T. Progression and regression of sleep-disordered breathing with changes in weight:the Sleep Heart Health Study. Arch Intern Med 2005; 165(20):2408-2413.
[54]Grunstein RR, Stenlof K, Hedner JA, et al. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep 2007;30(6):703-710.
[55]B.K.Jacobsen, S.F.Knutsen, K.Oda, et al. Obesity at age 20 and the risk of miscarriages, irregular periods and reported problems of becoming pregnant:the Adventist Health Study-2. Eur J Epidemiol 2012; 27:923-931.
[56]Wei S, Schmidt MD, Dwyer T. Obesity and menstrual irregularity:associations with SHBG, testosterone, and insulin. Obesity (Silver Spring).2009 May; 17(5):1070-1076.
[57]陈维真,朱康顺,罗辉.青少年肥胖女性血清睾酮与代谢综合征的关系[J].当代医学2010；9：55-57.
[58]Jenko-Praznikar Z, Petelin A, Jurdana M, et al. Serum bilirubin levels are lower in overweight asymptomatic middle-aged adults:An early indicator of metabolic syndrome?, Metabolism 2013, http://dx.doi.org/10.1016/j.metabol.2013.01.011.
[59]Wu Y, Li M, Xu M, et al. Low serum total bilirubin concentrations are associated with increased prevalence of metabolic syndrome in Chinese. J Diabetes 2011; 3:217-224.
[60]S.H. Choi, K.E. Yun, H.J. Choi. Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults. Nutrition, Metabolism & Cardiovascular Diseases 2013; 23:31-37.
[61]De Miguel E, Puig JG, Castillio C, et al. Diagnosis of gout in patients with asymptomatic hyperuricaemia:a pilot ultrasound study. Ann Rheum Dis 2012; 71(1):157-158.
[62]Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med.2007; 120:442-447.
[63]Nannipieri M, Cecchetti F, Anselmino M, et al. Expression of thyrotropin and thyroid hormone receptors in adipose tissue of patient with morbid obesity and/or type 2 diabetes:effects of weight loss. Int J Obes (Lond) 2009;33:1001-1006. Epub 2009 Jul 28.
[64]Reinehr T. Obesity and thyroid function. Mol Cell Endocrinol 2010; 316:165-171.
[65]Garten A., Schuster S.& Kiess W. The insulin-like growth factors in adipogenesis and obesity. Endocrinol. Metab. Clin. North Am.2012; 41:283-295.
[66]Cartwright, M. J. et al. Aging, depot origin, and preadipocyte gene expression. J. Gerontol. A. Biol. Sci. Med. Sci.2010; 65:242-251.
[67]Chen PH, Chen JD, Lin YC. A better parameter in predicting insulin resistance:Obesity plus elevated alanine aminotransferase. World J Gastroenterol 2009; 15(44):5598-5603.
[68]Roden M., Price T.B., Perseghin G., Petersen, K.F., et al. Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Invest.1996; 97:2859-2865.
[69]McQuaid S.E., Hodson L., Neville M.J., et al. Downregulation of adipose tissue fatty acid trafficking in obesity:A driver for ectopic fat deposition? Diabetes 2011; 60:47-55.
[70]Jon O.E., Michael D.J. Fat depots, free fatty acids, and dyslipidemia. Nutrients 2013; 5:498-508.
[71]Fernando Gerchman, Jenny Tong, Kristina M. Utzschneider, et al. Body mass index is associated with increased creatinine clearance by a mechanism independent of body fat distribution. J Clin Endocrinol Metab.2009; 94(10):3781-3788.
[72]Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes 2010; 17: 224-232.
[73]MacDonald AA, Herbison GP, Showell M, Farquhar CM. The impact of body mass index on semen parameters and reproductive hormones in human males:a systematic review with meta-analysis. Hum Reprod Update 2010; 16:293-311.
[74]Brand JS, van der Tweel I, Grobbee DE, et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome:a systematic review and meta-analysis of observational studies. Int J Epidemiol 2011; 40:189-207.
[75]Laaksonen DE, Niskanen L, Punnonen K, et al. Themetabolic syndrome and smoking in relation to hypogonadism in middle-aged men:a prospective cohort study. J Clin Endocrinol Metab 2005; 90:712-719.
[76]Sandeep D, Michael GM, Cecilia LM, et al. Testosterone concentrations in disbetic and nondiabetic obese men. Diabetes Care 2010; 33(6):1186-1192.
[1]Hirose H, Yamamoto Y, Seino-Yoshihara Y, et al. Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders. J Atheroscler Thromb,2010,17:1201-1211.
[2]Menzaghi C, Salvemini L, Paroni G, et al. Circulating high molecular weight adiponectin isoform is heritable and shares a common genetic background with insulin resistance in nondiabetic White Caucasians from Italy:evidence from a family-based study. J Intern Med,2010,267:287-294.
[3]Isao Saito, Kazumasa Yamagishi, Choy-Lye Chei, et al. Total and high molecular weight adiponectin levels and risk of cardiovascular disease in individuals with high blood glucose levels. Atherosclerosis 2013.04.014.
[4]Ussar S, Bezy O, Bliiher M. Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine. Diabetes,2012 Sep; 61(9):2289-2298.
[5]Gesta S, Bluher M, Yamamoto Y, et al. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Natl Acad Sci USA,2006; 103:6676-6681.
[6]Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010; 314:1-16.
[7]Bostrom P, Wu J, Jedrychowski MP, et al. A PGCl-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature,2012,481:463-468.
[8]The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care.1997; 20:1183-1197.
[9]Cheung BM. The hypertension-diabetes continuum. J Cardiovasc Pharmacol.2010; 55:333-539.
[10]Landsberg L,MolitchM. Diabetes and hypertension:pathogenesis, prevention and treatment. Clin Exp Hypertens.2004; 26:621-628.
[11]Mugo MN, Stump CS, Rao PG, et al. Hypertension and diabetes mellitus. In:Black HR, Elliott WJ, editors. Hypertension:A Companion to Braunwald's Heart Disease. Elsevier; 2007:409.
[12]Mazzone, T., Chait, A.& Plutzky, J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008; 371:1800-1809.
[13]Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52(2):453-462.
[14]ACCORD Study Group et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med.2010; 362:1563-1574.
[15]Farmer JA. Diabetic dyslipidemia and atherosclerosis:evidence from clinical trials. Curr Diab Rep 2008 Feb; 8(1):71-77.
[16]D. John Betteridge. Lipid control in patients with diabetes mellitus. Nature Reviews Cardiology 2011; 8:278-290.
[17]Salmela PI, Sotaniemi EA, Niemi M, Maentausta O. Liver function tests in diabetic patients. Diabetes Care 1984; 7:248-254.
[18]Meltzer AA, Everhart JE. Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans. Am J Epidemiol 1997; 146:565-571.
[19]Targher G, Bertolini L, Padovani R, Rodella S, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care.2007; 30:1212-1218.
[20]Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98:960-967.
[21]Westerbacka J, Corner A, Tiikkainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women:implications for sex differences in markers of cardiovascular risk. Diabetologia 2004; 47:1360-1369.
[22]Wannamethee SG, Shaper AG, Lennon L, et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005; 28:2913-2918.
[23]Ioannou GN, Weiss NS, Boyko EJ, et al. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 2005; 128:627-635.
[24]Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98:960-967.
[25]H.E. Resnick, G.L. Foster, J. Bardsley, R.E. Ratner, Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes,1999-2002:the National Health and Nutrition Examination Survey, Diabetes Care 2006; 29:531-537.
[26]R.B. D'Agostino Jr., R.F. Hamman, A.J. Karter, et al. Cardiovascular disease risk factors predict the development of type 2 diabetes:the insulin resistance atherosclerosis study, Diabetes Care 2004; 27:2234-2240.
[27]J.P. Despres,1. Lemieux, Abdominal obesity and metabolic syndrome, Nature 2006; 444: 881-887.
[28]H.N. Ginsberg, Y.L. Zhang, A. Hernandez-Ono. Metabolic syndrome:focus on dyslipidemia, Obesity (Silver Spring) 2006; 14 (Suppl.1):41S-49S.
[29]Diabetes Obesity Center of Excellence. Hypertriglyceridemia secondary to obesity and diabetes. Biochimica et Biophysica Acta 2012; 1821:819-825.
[30]Kannel WB. Lipids, diabetes, and coronary heart disease:insights from the Framingham Study. Am Heart J 1985;110:1100-1107.
[31]Asia Pacific Cohort Studies Collaboration. Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific resion. Diabetologia 2007; 50:2289-2297.
[32]Turner, R. C. et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus:United Kingdom Prospective Diabetes Study (UKPDS:23). BMJ 1998; 316:823-828.
[33]Howard BV, Robbins DC, Sievers ML, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL:the Strong Heart Study. Arterioscler Thromb Vasc Biol 2000 Mar; 20(3):830-835.
[34]Peter H, Peter R, Richard JJ, et al. Serum uric acid as a new player in the development of diabetic nephropathy. Journal of Renal Nutrition 2011; 21(1):124-127.
[35]United States Renal Data System. Available at:www.usrds.org.2008.
[36]Parving H-H, Mauer M, Ritz E. Diabetic nephropathy. In:Brenner BM (ed.):Brenner & Rector's The Kidney,8th ed. Boston, MA:WB Saunders,2008, pp 1265-1298.
[37]Perlstein TS, Gumieniak O, Hopkins PN, et al. Uric acid and the state of the intrarenal renin-angiotensin systemin humans. Kidney Int 2004; 66:1465-1470.
[38]Hovind P, Rossing P, Tarnow L, et al. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetesf an inception cohort study. Diabetes 2009; 58:1668-1671.
[39]Jalal DI, Rivard CJ, Johnson RJ, et al. Serumuric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes:findings from the coronary artery calcification in type 1 diabetes study. Nephrol Dial Transplant 2010; 25:1865-1869.
[40]Rosolowsky ET, Ficociello LH, Maselli NJ, et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2008; 3:706-713.
[41]Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment:insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
[42]Zhu N, Pankow JS, Ballantyne CM, et al. High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. J Clin Endocrinol Metab 2010; 95:5097-5104.
[43]Bluher S, Ziotopoulou M, Bullen JW Jr, et al. Responsiveness to peripherally administered melanocortins in lean and obese mice. Diabetes 2004; 53:82-90.
[44]Li S, Shin JJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes:a systematic review and meta-analysis. JAMA 2009; 302:179-188.
[45]Schulze MB, Shai I, Rimm EB, et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54:534-539.
[46]Cnop M, Utzschneider KM, Carr DB, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins:evidence for independent roles of age and sex. Diabetologia 2003; 46:459-469.
[47]Yoo HJ, Hwang SY, Cho GJ,et al. Association of glypican-4 with body fat distribution, insulin resistance, and non-alcoholic fatty liver disease. J Clin Endocrinol Metab.2013 Apr 30. [Epub ahead of print].
[48]Yeon-Kyung Choi, Mi-Kyung Kim, Kwi Hyun Bae, et al. Serum irisin levels in new-onset type 2 diabetes[J]. Diabetes Research and Clinical Practice,2012,100:96-101.
[49]Zhang HJ, Zhang XF, Ma ZM, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults[J]. J Hepatol,2013 May 8.
[50]Cunha A. Basic research:Irisin—behind the benefits of exercise. Nat Rev Endocrinol,2012; 8(4): 195.
[51]Andreas S, Tobias H, Miriam GS, et al. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity-Correlation with body mass index. Peptides 2013; 39: 125-130.
[52]Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans:I. Predictors of circulating concentrations in serum and plasma and Ⅱ. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61:1725-1738.
[53]卢东晖,张帆,阴慧清.2型糖尿病胰岛素抵抗与TNF-α、肥胖的关系[J].中华全科医学,2008,11(6)：1113-1114.
[54]Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010;316,129-139.
[1]中国肥胖问题工作组,中国学龄儿童青少年超重、肥胖筛查体重指数值分类标准[J].中华流行病学杂志,2004,25(2)：97-102.
[2]中国肥胖问题工作组数据汇总分析协作组.我国成人体重指数和腰围对相关疾病危险因素异常的预测价值：适宜体重指数和腰围切点的研究[J].中华流行病学杂志,2002,23(1)：5-10.
[3]Louis JA. Classification of obesity and assessment of obesity-related health risks[J]. Obetity Research,2002,10(2):105S-115S.
[4]赵青,张抒扬.肥胖症与心血管疾病[J].中国医学科学院学报,2012,34(4)：431-436.
[5]Rocha VZ, Floco EJ. Inflammatory concepts of obesity[J]. Int J Inflam,2011,2011:529061.
[6]Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002; 346:802.
[7]Vidar Hjellvik, Solveig Sakshaug, Hanne Strom. Body mass index, triglycerides, glucose, and blood pressure as predictors of type 2 diabetes in a middle-aged Norwegian cohort of men and women. Clinical Epidemiology 2012; 4:213-224.
[8]Robyn J, Daniel J, Jonathan E, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care,2003,26:1731-1737.
[9]Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men:impact on cardiovascular disease and diabetes. J Epidemiol Community Health 2005; 59(2):134-139.
[10]Fujimoto WY, Jablonski KA, Bray GA, et al. Diabetes Prevention Program Research Group. Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes 2007; 56(6):1680-1685.
[11]Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA 2009; 302:401-411.
[12]Doll S, Paccaud F, Bovet P, Burnier M, Wietlisbach V. Body mass index, abdominal adiposity and blood pressure:consistency of their association across developing and developed countries. Int J Obes Relat Metab Disord 2002; 26:48-57.
[13]Sorof J, Daniels S. Obesity hypertension in children:a problem of epidemic proportions. Hypertension 2002; 40:441.
[14]Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk:the Framingham experience. Arch Intern Med 2002; 162:1867.
[15]Sun Z, Zheng L, Detrano R, et al. Risk of progression to hypertension in a rural Chinese women population with prehypertension and normal blood pressure. Am J Hypertens 2010; 23:627-632.
[16]陈纪春,段秀芳,黄广勇等.体重指数与不同亚型高血压的关系[J].高血压杂志,2006,6(14)：432-435.
[17]Mancia G, De BG, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension(ESH) and of the European Society of Cardiology(ESC). J Hypertens 2007; 25: 1105-1187.
[18]SjostromL, NarbroK, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741-752.
[19]Siebenhofer A, Horvath K, Jeitler K, et al. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev 2009; Jul 8:CD007654.
[20]Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease:pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006; 26:968.
[21]Harel Z, Riggs S, Vaz R, et al. Isolated low HDL cholesterol emerges as the most common lipid abnormality among obese adolescents. Clin Pediatr (Phila) 2010; 49:29.
[22]Lauer RM, Lee J, Clarke WR. Factors affecting the relationship between childhood and adult cholesterol levels:the Muscatine Study. Pediatrics 1988; 82:309-318.
[23]Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk:the Framingham experience. Arch Intern Med 2002; 162(16): 1867-1872.
[24]Fox CS, Pencina MJ, Wilson PW, et al. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care 2008;31(8):1582-1584.
[25]Iribarren C, Darbinian JA, Lo JC, et al. Value of the sagittal abdominal diameter in coronary heart disease risk assessment:cohort study in a large, multiethnic population. Am J Epidemiol 2006;164:1150.
[26]McGill HC Jr, McMahan CA, Herderick EE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002; 105:2712.
[27]Madala MC, Franklin BA, Chen AY, et al. Obesity and age of first non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2008; 52:979.
[29]Chen K, Lindsey JB, Khera A, et al. Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis:observations from the Dallas Heart Study. Diab Vasc Dis Res 2008;5(2):96-101.
[30]Ilanne-Parikka P, Eriksson JG, Lindstrom J, et al. Finnish Diabetes Prevention Study Group. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care 2008;31(4):805-807.
[31]Phelan S, Wadden TA, Berkowitz RI, et al. Impact of weight loss on the metabolic syndrome. Int J Obes 2007;31:1442-1448.
[32]Foster GD, Sanders MH, Millman R, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care 2009; 32:1017.
[33]Verhulst SL, Schrauwen N, Haentjens D, et al. Sleep-disordered breathing in overweight and obese children and adolescents:prevalence, characteristics and the role of fat distribution. Arch Dis Child 2007; 92:205.
[34]Resta O, Foschino-Barbaro MP, Legari G, et al. Sleep-related breathing disorders, loud snoring and excessive daytime sleepiness in obese subjects. Int J Obes Relat Metab Disord 2001;25(5):669-675.
[35]Pillar G, Shehadeh N. Abdominal fat and sleep apnea:the chicken or the egg? Diabetes Care 2008;31(suppl 2):S303-S309.
[36]Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000;284(23):3015-3021.
[37]Grunstein RR, Stenlof K, Hedner JA, Peltonen M, Karason K, Sjostrom L. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep 2007;30(6):703-710.
[38]Linnemann B, Zgouras D, Schindewolf M et al. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism:results from the German MAISTHRO Registry. Blood Coagul Fibrinolysis 2008; 19:159-165.
[39]Kabrhel C, Varraso R, Goldhaber SZ, Rimm EB. Prospective study of BMI and the risk of pulmonary embolism in women. Obesity 2009; 17(11):2040-2046.
[40]Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005; 118(9):978-980.
[41]Eichinger S, Hron G, Bialonczyk C, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008.
[42]Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86(1):452-463.
[43]Konstantinides S, Schafer K, Neels JG, Dellas C, Loskutoff DJ. Inhibition of endogenous leptin protects mice from arterial and venous thrombosis. Arterioscler Thromb Vasc Biol 2004;24:2196-2201.
[44]Napoleone E, A DIS, Amore C et al. Leptin induces tissue factor expression in human peripheral blood mononuclear cells:a possible link between obesity and cardiovascular risk? J Thromb Haemost 2007; 5:1462-1468.
[45]Cushman M, Kuller LH, Prentice R et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292:1573-1580.
[46]Speiser PW, Rudolf MC, Anhalt H, et al. Childhood obesity. J Clin Endocrinol Metab 2005; 90:1871.
[47]Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of non-alcoholic fatty liver disease in children:a follow-up study for up to 20 years. Gut 2009; 58:1538.
[48]Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191(2):235-240.
[49]Riquelme A, Arrese M, Soza A, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 2009; 29(1):82-88.
[50]Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006; 26(7):856-863.
[51]Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006; 82(967):315-322.
[51]Liu B, Balkwill A, Spencer E, Beral V, Million Women Study Collaborators. Relationship between body mass index and length of hospital stay for gallbladder disease. J Public Health (Oxf)2008;30(2):161-166.
[52]Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr 2004;80(1):38-44.
[53]Ehrmann DA. Polycystie ovary syndrome. N Engl J Med,2005,352:1223-1236.
[54]Mehrabian F, Khani B, Kelishadi R, Ghanbari E. The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria. Endokrynol Pol 2011; 62:238-242.
[55]Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93:162-168.
[56]Balen AH, Conway GS, Kaltsas G et al. Polycystic ovary syndrome:the spectrum of the disorder in 1741 patients. Hum Reprod 1995; 10:2107-2111.
[57]Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome:relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf) 1994; 41:463-471.
[58]Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:48-53.
[59]Himelein MJ, Thatcher SS. Depression and body image among women with polycystic ovary syndrome. J Health Psychol 2006; 11:613-625.
[60]Barry JA, Kuczmierczyk AR, Hardiman PJ. Anxiety and depression in polycystic ovary syndrome:a systematic review and meta-analysis. Hum Reprod 2011; 26:2442-2451.
[61]Weiner CL, Primeau M, Ehrmann DA. Androgens and mood dysfunction in women:comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med 2004; 66: 356-362.
[62]Rasgon NL, Rao RC, Hwang S et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord 2003; 74:299-304.
[63]Yucel A, Noyan V, Sagsoz N. The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2006; 126:81-86.
[64]CresswellJL, Barker DJ, Osmond C, et al. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet,1997,350:1131-1135.
[65]Maggard MA, Yermilov I, Li Z, et al. Pregnancy and fertility following bariatric surgery:a systematic review. JAMA 2008; 300:2286.
[66]Sallmen M, Sandier DP, Hoppin JA, et al. Reduced fertility among overweight and obese men. Epidemiology 2006; 17:520-523.
[67]Swan SH, Elkin EP, Fenster L. The question of declining sperm density revisited:an analysis of 101 studies published 1934-1996. Environ Health Perspect 2000; 108:961-966.
[68]Corona G, Mannucci E, Schulman C, et al. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol 2006; 50:595-604; discussion 604.
[69]Jensen TK, Andersson AM, Jorgensen N, et al. Body mass index in relation to semen quality and reproductive hormones among 1,558 danish men. Fertil Steril 2004; 82:863-870.
[70]Martini AC, Tissera A, Estofan D, et al. Overweight and seminal quality:a study of 794 patients. Fertil Steril 2010; Jan 5.
[71]Smit M, Romijn JC, Wildhagen MF, et al. Sperm chromatin structure is associated with the quality of spermatogenesis in infertile patients. Fertil Steril 2009.
[72]Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ. Association of bioavailable, free, and total testosterone with insulin resistance:influence of sex hormone-binding globulin and body fat. Diabetes Care 2004; 27:861-868.
[73]Niskanen L, Laaksonen DE, Punnonen K, et al. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004; 6:208-215.
[74]Sharman MJ, Volek JS. Weight loss leads to reductions in inflammatory biomarkers after a very-low-carbohydrate diet and a low-fat diet in overweight men. Clin Sci (Lond) 2004; 107: 365-369.
[75]Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105:804-809.
[76]Rexrode KM, Hennekens CH, Willett WC, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997; 277:1539.
[77]Kurth T, Gaziano JM, Berger K, et al. Body mass index and the risk of stroke in men. Arch Intern Med 2002; 162:2557.
[78]Gusrafson B, Hammarstedt a, Andersson CX, et al. Inflamed adipose tissue:a culprit underlying the metabolic syndrome and atherosclerosis[J]. Arterioscler Thromb Vasc Biol,2007,27(11): 2276-2283.
[79]Song YM, Sung J, Davey Smith G, Ebrahim S. Body mass index and ischemic and hemorrhagic stroke:a prospective study in Korean men. Stroke 2004; 35:831-836.
[80]Zhou M, Offer A, Yang G, Smith M, Hui G, Whitlock G et al. Body mass index, blood pressure, and mortality from stroke:a nationally representative prospective study of 212 000 Chinese men. Stroke 2008; 39:753-759.
[81]Pham TM, Fujino Y, Tokui N, Ide R, Kubo T, Shirane K et al. Mortality and risk factors for stroke and its subtypes in a cohort study in Japan. Prev Med 2007; 44:526-530.
[82]Funada S, Shimazu T, Kakizaki M, Kuriyama S, Sato Y, Matsuda-Ohmori K et al. Body mass index and cardiovascular disease mortality in Japan:the Ohsaki study. Prev Med 2008; 47: 66-70.
[83]Calle EE. Obesity and cancer[J]. BMJ,2007;335:1107-1108.
[84]Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity and mortality form cancer in a prospectively studied cohort of US adults[J]. N Engl J Med,2003; 348:1625-1638.
[85]Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer:a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569.
[86]胡红琳.肥胖人群抵抗素表达与血清游离脂肪酸、肿瘤坏死因子、脂联素水平的研究.临床荟萃,2007,22：852-855.
[87]Parker ED, Folsom AR. Intentional weight loss and incidence of obesity-related cancers:the Iowa Womens Health Study. Int J Obes Relat Metab Disord,2003,27(12):1447-1452.
[88]Grotle M, Hagen KB, Natvig B, et al. Obesity and osteoarthritis in knee, hip and/or hand:an epidemiological study in the general population with 10 years follow-up. BMC Musculoskelet Disord 2008; 9:132.
[89]Petry NM, Barry D, Pietrzak RH, Wagner JA. Overweight and obesity are associated with psychiatric disorders:results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med 2008;70(3):288-297.
[90]Strine TW, Mokdad AH, Dube SR, et al. The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults. Gen Hosp Psychiatry 2008;30(2):127-137.
[91]Simon GE, Ludman EJ, Linde JA, et al. Association between obesity and depression in middle-aged women. Gen Hosp Psychiatry 2008;30(1):32-39.
[92]Eisenberg ME, Neumark-Sztainer D, Story M. Associations of weight-based teasing and emotional well-being among adolescents. Arch Pediatr Adolesc Med 2003; 157:733.
[93]Strauss RS. Childhood obesity and self-esteem. Pediatrics 2000; 105:e15.
[94]Becker ES, Margraf J, Turke V, et al. Obesity and mental illness in a representative sample of young women. Int J Obes Relat Metab Disord 2001; 25 Suppl 1:S5.
[95]Erickson SJ, Robinson TN, Haydel KF, Killen JD. Are overweight children unhappy?:Body mass index, depressive symptoms, and overweight concerns in elementary school children. Arch Pediatr Adolesc Med 2000; 154:931.
[96]Staffieri JR. A study of social stereotype of body image in children. J Pers Soc Psychol 1967; 7:101.
[97]Griffiths LJ, Wolke D, Page AS, et al. Obesity and bullying:different effects for boys and girls. Arch Dis Child 2006; 91:121.
[98]Stunkard A, Burt V. Obesity and the body image. Ⅱ. Age at onset of disturbances in the body image. Am J Psychiatry 1967; 123:1443.
[99]Gortmaker SL, Must A, Perrin JM, et al. Social and economic consequences of overweight in adolescence and young adulthood. N Engl J Med 1993; 329:1008.
[100]Sargent JD, Blanchflower DG. Obesity and stature in adolescence and earnings in young adulthood. Analysis of a British birth cohort. Arch Pediatr Adolesc Med 1994; 148:681.
[101]Wang Y. Is obesity associated with early sexual maturation? A comparison of the association in American boys versus girls. Pediatrics 2002; 110:903.
[102]Speiser PW, Rudolf MC, Anhalt H, et al. Childhood obesity. J Clin Endocrinol Metab 2005; 90:1871.